Aconitase And Oxidative Stress

713 Words2 Pages

Oxidative stress
High oxidative a stress is known to cause global cellular damage by creating reactive oxygen species (ROS) which causes damage to proteins, lipids and DNA (15, 82). Oxidative stress increases protein phosphorylation, causing changes to signaling pathways. For example, several phosphatases involved in cancer, apoptosis and aging are inactivated under conditions of high oxidative stress (26). ROS is a known contributor to several diseases including Alzheimer’s, Parkinson’s, Huntington’s, kidney disease, and T2DM (25, 27, 105). Known mediators of oxidative stress include transition metals and mitochondrial dysfunction (15, 27). In this project, I will be studying how cellular iron regulation causes an increase in oxidative stress, contributing to cellular damage and disease. Aconitase is an important mediator of oxidative stress, metabolism and iron regulation.
Aconitase is an enzyme in the TCA cycle that is located in both the cytosol and mitochondria. It is a widely used marker of oxidative stress and is an important point of iron regulation (fig. 3). Aconitase is sensitive to oxidative stress because it contains iron sulfur clusters that are released under conditions of low iron or high oxidative stress. After aconitase releases its Fe-S clusters, it undergoes a conformational change and becomes iron regulatory protein 1 (IRP-1). This increases cellular iron absorption and decreases iron storage through regulating iron transport and storage proteins.
Aconitase catalyzes the conversion of citrate to isocitrate in the mitochondria and cytosol. In the mitochondria, aconitase is required for the TCA cycle to continue. In the case of high mitochondrial ROS production, aconitase becomes oxidized and no longer functions...

... middle of paper ...

...nd is the most likely candidate for increased ROS observed with doxorubicin administration. Through these mechanisms, doxorubicin works well in slowing the progression of cancer. However, side effects of this drug limit the total dosage a patient can receive.
Four therapies have been described to decrease the muscle toxicity of doxorubicin. First, use of the iron chelator dexrazoxane decreases muscle toxicity (36, 89).Second, aerobic exercise has been shown to protect against doxorubicin induced skeletal muscle apoptosis through decreasing autophagy signaling (50, 84, 85). Third, the mitochondrial antioxidant SS31 protects against doxorubicin induced apoptosis (32). Fourth, pretreatment of metformin, an anti-diabetic drug, decreases cardiomyocyte apoptosis (7, 8). The interaction of doxorubicin and metformin will be discussed in greater detail in upcoming sections.

More about Aconitase And Oxidative Stress

Open Document